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Abstract 
Introduction: About 30-40% of GERD patients report an inadequate response to proton pump 
inhibitors (PPIs) due to their suboptimal pharmacological profiles. Recently, a new synthesized P-
CABs, vonoprazan, showed higher suppression of gastric acid secretion as compared to 
lansoprazole.  
 
Areas covered: This review provides an update on the pharmacokinetic properties of vonoprazan 
and their correlates with pharmacodynamics; preliminary data on the therapeutic efficacy of 
vonoprazan as compared to lansoprazole in GERD patients  
 
Expert opinion: At variance from all available PPIs, vonoprazan acts directly on H+,K+-ATPase 
irrespectively of its activity, providing a fast onset of action without requiring acid activation and 
specific administration timing. Clinical and pharmacological investigations have confirmed a more 
rapid, potent and prolonged inhibition of acid secretion, including a better nighttime acid control, 
and a less antisecretory variability, as compared with PPIs. Preliminary data in patients with erosive 
esophagitis (EE) have shown the non-inferiority of vonoprazan to lansoprazole in terms of symptom 
relief and healing rate. Since these pharmacokinetic advantages, it is expected that it will have a 
significant favorable impact on GERD management. However, the clinical use of vonoprazan raises 
also some issues about its efficacy and safety in the long-term that deserve verification and careful 
investigation.  
 
  
Keywords: Vonoprazan, Gastro-esophageal Reflux Disease, GERD, Pharmacokinetics, P-CABs  
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 Article highlights box 
• About 30-40% of gastro-esophageal reflux disease (GERD) patients report an inadequate 
response to proton pump inhibitors drugs due to their suboptimal pharmacological 
profiles.  
• Recently, a new synthesized Potassium-competitive acid blocker, Vonoprazan, has been 
developed by Takeda Pharmaceuticals with preliminary data showing higher suppression 
of gastric acid secretion and similar efficacy as well as safety as compared to 
lansoprazole in GERD patients 
• At variance from all the available PPIs, vonoprazan acts directly on H+,K+-ATPase 
irrespectively of their activity, providing a fast onset of action without requiring acid 
activation and specific timing with respect to food intake.  
• Clinical and pharmacological investigations have confirmed a more rapid, potent and 
prolonged inhibition of acid secretion by vonoprazan, including a better nighttime acid 
control, as compared with PPIs, with a less antisecretory variability and a lower risk of 
drug interactions among patients.  
• First clinical data in patients with erosive esophagitis (EE) have shown that the healing 
rate after two weeks of treatment with vonoprazan was higher than lansoprazole, with 
the proportion of patients with healed EE displaying a higher trend in the vonoprazan 
group, in patients with more severe esophagitis.  
• Further studies investigating the efficacy and safety in the long-term of vonoprazan in 
patients with acid-related disorders are required 
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 1. Introduction 
Gastroesophageal reflux disease (GERD) develops when the reflux of gastric contents into the 
esophagus causes troublesome symptoms and/or complications.[1-3] Population-based studies 
suggest that GERD prevalence is increasing worldwide, with relevant impact on quality of life and 
health care costs.[4]  
The pathogenesis of GERD is multifactorial in nature, mainly involving dysfunctions of the 
esophagogastric junction, ineffective esophageal acid and bolus clearance, impaired mucosal 
defensive factors, and esophageal hypersensitivity.[5] Moreover, characteristics and components of 
the refluxate play a pivotal role in the pathological consequences of GERD.[6]  
To date, acid suppression therapy represents the mainstay of GERD treatment.[7, 8] 
Pathophysiological studies have indeed shown that the vast majority of GERD symptoms are 
associated with acid reflux episodes,[9] and that the exposure of esophageal mucosa to acid 
increases progressively in parallel with the increasing severity of GERD presentation.[10, 11]  
The breakthrough in the treatment of acid-related diseases was the discovery of histamine-2-
receptor antagonists (H2RAs) in the mid-1970s.[12, 13] However, these drugs, which act through 
the blockade of only one of the three main pathways regulating gastric acid secretion, displayed 
soon a number of significant limitations, including a relatively short duration of action, an 
incomplete inhibition of post-prandial gastric acid secretion, a decline in the antisecretory effect 
(i.e., tolerance), and a post-treatment rebound acid hypersecretion.[14-17] 
The identification of the proton pump (H+,K+-ATPase) as the final step of gastric acid secretion 
and the development of its blockers (proton pump inhibitors, PPIs) led to a significant improvement 
in the management of acid-related disorders.[18] Indeed, PPIs provide a greater and longer lasting 
effect on acid suppression than H2RAs,[19] with a more potent symptomatic relief and esophagitis 
healing in high proportions of GERD patients.[19-21] Furthermore, PPIs control both basal and 
food-stimulated acid secretion, and they are not subjected to development of tolerance.[17, 18, 22] 
PPIs represent currently the mainstay of GERD treatment.[7] However, failure or incomplete 
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 response to these drugs has been reported from 10 to 40% of GERD patients.[23, 24] Although the 
causes of refractoriness to PPIs are multiple in nature,[25-28] they can be partly linked to 
shortcomings and limitations pertaining to PPIs, as discussed in detail below.  
Overall, the above considerations underscore the need for new options in the therapeutic 
management of GERD. In this context, current research is being focused on potassium-competitive 
acid blockers (P-CABs). Among them, a novel P-CAB, vonoprazan, designated also as TAK-438 
(Box 1), has been developed.[29, 30] In the present article, the available information on vonoprazan 
have been reviewed to provide an appraisal of its pharmacokinetic profile, antisecretory activity and 
efficacy in GERD patients. Special attention has been paid to comparative data with lansoprazole in 
terms of acid inhibition, relief of GERD symptoms and mucosal healing. 
 
2. Role of PPIs in GERD: main determinants of their antisecretory effect and limitations 
PPIs represent the first choice medical treatment for GERD. In this setting, the main therapeutic 
indications for PPI use include the induction of symptom remission and esophagitis healing, as well 
as the maintenance of symptom control and prevention of esophagitis recurrence.[7, 31-33]  
PPIs are targeted at selectively and irreversibly blocking the gastric H+,K+-ATPase, which is the 
final step in acid secretion. Of note, their inhibitory action can be exerted only on active protonic 
pumps, that is when, under appropriate stimuli, H+,K+-ATPase translocates to the apical membrane 
of parietal cells and operates to decrease the pH of secretory canalicula to approximately 1.0.[34, 
35] Under resting conditions, parietal cells can initially escape the acid inhibitory action of PPIs, 
and therefore a full antisecretory effect is usually obtained after administration of repeated doses 
(steady-state inhibition is achieved within 3 to 5 days).[36, 37]  
With regard for their mechanism of action, PPIs are weak base prodrugs (substituted 
pyridylmethylsulfinyl benzimidazoles with pKa values ranging from 3.8 to 4.5) that, upon oral 
administration enter the systemic blood circulation and accumulate in the strong acid 
microenvironment of secretory canalicula, where they undergo activation through an acid-catalyzed 
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 conversion into a thiophylic cyclic sulfonamide that is a highly reactive molecular species.[18] This 
compound then inhibits H+-K+-ATPase by means of covalent disulfide bonds with cysteine 
residuals exposed in the luminal domain of the proton pump.[34] Since PPIs are acid-labile 
compounds and proton pump blockade requires their acid-dependent activation within the secretory 
canalicula of parietal cells, these drugs must be administered orally as gastroprotected formulations, 
to protect them from acid degradation within the gastric lumen.[36, 37]  
When considering PPI pharmacokinetics, there is evidence that the area under the plasma 
concentration-time curve (AUC) represents a major determinant of the magnitude of the acid 
inhibitory effect, and that the plasma elimination half-life (t½) is a major determinant of the effect 
duration. Despite their short plasma t½ of 60-90 minutes, the covalent binding of PPIs with proton 
pumps accounts for their long-lasting acid inhibitory effect. However, gastric proton pumps have a 
half-life of 50 hours and about one third of them are replaced by new biosynthesis every day. Thus, 
the new proton pumps synthetized at night-time cannot be exposed to PPIs, even when these drugs 
are administered twice daily, with a consequent persistence of low volume acid secretion (nocturnal 
acid breakthrough).[37] Most PPIs are known also to undergo hepatic metabolism by the CYP 
system. In this regard, CYP2C19 gene polymorphisms have been shown to influence the 
pharmacokinetics of some PPIs, thus generating relevant inter-individual variability of their 
pharmacodynamics and clinical activity.[38, 39]  
PPIs can interfere with other drugs because of their inhibitory effect on gastric acid secretion or 
their inhibition of enzymes involved in drug metabolism.[40] 
With respect to safety, most studies on short- and long-term PPI use have provided reassuring 
data.[41] Nevertheless, adverse effects associated with long-term PPI use deserve careful 
consideration.[42] 
Overall, current PPIs cannot be considered ideal drugs for GERD due to their limitations, including: 
1) lack of targeting of key GERD pathophysiological mechanisms; 2) suboptimal efficacy of 
symptom control; 3) suboptimal pharmacological profiles in terms of intake at appropriate time 
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 relative to meals, delay in effect onset, low bioavailability, variable liver metabolism, and nocturnal 
acid breakthrough.[43-45] 
To date, new pharmaceutical strategies to overcome PPI limitations in GERD therapy have been 
focused on: 1) new formulations of current PPIs; 2) new PPIs (i.e. tenatoprazole, ilaprazole); 3) new 
proton pump blockers endowed with different mechanisms of action than benzimidazole PPIs 
(PCABs).[43, 46]  
 
3. PCABs 
P-CABs comprise currently a heterogeneous group of molecules able to inhibit selectively the 
gastric H+,K+-ATPase by a specific K+-competitive reversible mechanism.[47, 48] 
P-CABs are weak bases endowed with a higher pKa than PPIs. Accordingly, P-CABs are highly 
concentrated in the acidic secretory canalicula of parietal cells, and are instantly protonated when 
exposed to the acidic environment. Once in the protonated form, P-CABs are thought to bind and 
inhibit the K+ site of H+,K+-ATPase.[49] As anticipated above, PPIs are prodrugs that exert their 
inhibitory activity after undergoing an acid-catalyzed conversion to a reactive species. At variance, 
P-CABs do not require any molecular rearrangement under acidic conditions, thus implying that 
they are more stable and not subjected to degradation at the pH levels achievable in the gastric 
lumen. As a result, P-CABs can be administered by oral route without requiring gastroprotective 
formulations. Moreover, PCABs achieve rapidly peak plasma concentrations after oral 
administration, their control on gastric pH throughout the 24-h period is more stable than PPIs, and 
the duration of their antisecretory effect is related to their plasma t½.[50]  
P-CABs have been shown to inhibit the K+-stimulated dephosphorylation of H+,K+-ATPase by a 
competitive displacement of K+ from the phosphorylated proton pump.[51] This mechanism allows 
P-CABs to rapidly block the H+,K+-ATPase in its mid-cycle, without requiring proton pump 
activation, thus resulting in a more rapid acid inhibition and elevation of gastric pH to higher levels 
than PPIs.[52] In line with this expectation, PCABs displayed a faster onset of acid inhibitory 
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 action, when compared to PPIs, reaching a full antisecretory effect since the first dose, within the 
first day.[53, 54]  
The imidazopyridine SCH28080 was the first compound developed as a P-CAB. It was shown to be 
a pure K+ competitive inhibitor of the gastric proton pump with a pKa of 5.5. Accordingly, 
SCH28080 displayed an efficient acid inhibitory action and a selective accumulation in the acid 
compartment of parietal cells.  Nevertheless, it was never marketed owing to its hepatoxicity.[55] 
Afterwards, other similar drugs have been synthesized and evaluated, such as revaprazan (a 
pyrimidine derivative) and AZD0865 (another imidazopyridine compound). However, despite a 
good acid inhibitory activity, these drugs were limited by their rapid dissociation rate from the 
proton pump that was responsible for a short duration of acid inhibition and, consequently, an 
incomplete control of gastric acid secretion over 24-h, particularly at night-time, when administered 
on a once-a-day basis.[56, 57] 
Acknowledging the benefits of P-CABs, as compared to PPIs, Takeda Pharmaceutical Company 
Limited (Japan) recently developed a novel and potent compound (vonoprazan), endowed with a 
different chemical structure from previous P-CABs, with the goal of overcoming the shortcomings 
of its predecessors. 
 
4. Vonoprazan 
Vonoprazan is a pyrrole derivative, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-
N-methylmethanamine monofumarate (designated also as TAK-438), characterized by a slightly 
slower onset of action, as compared to previous P-CABs, while displaying higher affinity for gastric 
H+,K+-ATPase and a slower dissociation rate.[58]  
 
4.1 Pharmacodynamics  
 
4.1.1 Studies in preclinical models 
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 Vonoprazan is a potent K+-competitive inhibitor of the gastric H+,K+-ATPase, with an inhibitory 
constant (Ki) of 10 nM at pH 7, and 3 nM at pH 6.5.[58, 59] When compared with SCH28080 and 
lansoprazole, under in vitro weakly acidic conditions (pH 6.5), all three compounds inhibited the 
activity of gastric H+,K+-ATPase in a concentration-dependent manner. However, the inhibitory 
activity of vonoprazan was the most potent. Moreover, under neutral conditions (pH 7.5), the 
inhibitory activity of SCH28080 and lansoprazole decreased, while that of vonoprazan remained 
almost the same as that recorded at pH 6.5.[59] Indeed, the pKa value of vonoprazan (9.37) is 
higher than that of previous P-CABs, and therefore it is expected to be protonated instantly and 
exert a potent inhibitory activity on gastric proton pumps even in a neutral environment.[59]  
The binding rate of vonoprazan in vitro reaches the plateau of inhibition within 200 s. However, 
such a slow action onset does not appear to affect its efficacy on diurnal pH control in vivo.[58, 59] 
As an additional advantage, vonoprazan has a slower dissociation rate from proton pumps than 
other P-CABs that translates into a longer duration of its acid inhibitory activity. Shin et al.[58] 
observed that the dissociation half-life of vonoprazan was inversely related with the concentration 
of potassium chloride (KCl) in the incubation medium (12.5 h, 7.5 h and 3 h at 10 mM, 20 mM and 
30 mM KCl, respectively).[58] At higher concentrations of vonoprazan, higher concentrations of 
KCl were required to maintain the same dissociation rate. Of note, Keeling et al.[60] reported that 
about 60% of SCH28080 dissociated from proton pumps within 2 min in 10 mM KCl. As shown by 
Shin et al.,[58] in the presence of acidic media the inhibitory effect of vonoprazan on proton pumps 
is less sensitive to KCl, since at lower pH there is a predominance of the protonated form of 
vonoprazan, which is endowed with a stronger binding affinity, and thus it is less influenced by KCl 
concentration. According to the hypothesis that H+,K+-ATPase is commonly exposed on the apical 
membrane of parietal cells at 15 mM KCl under conditions of stimulated gastric acid secretion, the 
expected in vivo dissociation rate of vonoprazan should be longer than 7.5 h. Therefore, when 
translating these in vitro findings to the clinical setting, a stable acid inhibition is expected to occur 
after a single administration of vonoprazan.[58] To describe whether vonoprazan binding to gastric 
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 H+,K+-ATPase was covalent or reversible in nature, Shin et al.[58] exposed the gastric pump to 
vonoprazan and, subsequently, to [14C]-labeled vonoprazan. After precipitation of 
[14C]vonoprazan-bound enzyme, 99% of [14C]vonoprazan and only 1% of vonoprazan were found 
in the supernatant, thus substantiating the reversible inhibition of the H+,K+-ATPase.[58] 
Matsukawa et al.[61] investigated the accumulation of vonoprazan in the canalicula of parietal cells 
by comparison with lansoprazole in primary cultured rabbit gastric glands. As expected, 
lansoprazole accumulation was dependent on acid secretion and higher under the active than under 
the resting conditions of proton pumps. Under these conditions, both lansoprazole and vonoprazan 
inhibited acid secretion in a concentration-dependent manner. However, vonoprazan was confirmed 
to be a more potent inhibitor than lansoprazole (IC50 0.30 vs 0.76 µM). Moreover, vonoprazan 
accumulated in both resting and stimulated glands more than lansoprazole, and its clearance was 
slower. In particular, when drug clearance was evaluated by means of [14C]-labeled compounds, 
the radioactive ratio of lansoprazole at 24-h over the baseline was higher than that of vonoprazan. 
Such a result might be explained by the covalent binding of lansoprazole against the reversible 
inhibition operated by P-CABs. However, the amount of vonoprazan retention at 24-h was greater 
than that of lansoprazole. Of note, in this study the use of cultured gastric glands allowed to 
measure the effective accumulation and clearance of test drugs for a longer period, as compared to 
data obtained from acutely isolated gastric glands. Based on these data, it could be hypothesized 
that vonoprazan is able to generate a stronger and more prolonged inhibition, owing to its large 
accumulation and slow clearance in gastric glands.[61] 
With regard for selectivity, vonoprazan has been shown to not inhibit Na+,K+-ATPase due to its 
high affinity for H+,K+-ATPase. By contrast, lansoprazole can exert a minimal inhibitory action on 
Na+,K+-ATPase.[58, 59] To examine further the binding selectivity of vonoprazan for the gastric 
H+,K+-ATPase and its slow dissociation rate, Scott et al.[62] performed an autoradiography of 
vonoprazan binding and a molecular modelling of the proton pump. They observed that, at variance 
from omeprazole, labelling of rabbit gastric glands with [14C]vonoprazan did not change under 
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 resting or stimulated conditions. Vonoprazan binding was therefore independent of acid secretion, 
while acid activation is required for PPIs. Moreover, the selective labelling of parietal cells, 
regardless of the active or inactive state of H+,K+-ATPase, showed that it is the high affinity of 
vonoprazan that determines its binding selectivity, and not the pH within the canalicular 
compartment.[62]  
In their study, Scott et al.[62] tried to identify the mechanism responsible for the high affinity of 
vonoprazan by a modelling of drug binding to the H+,K+-ATPase. The kinetic analysis of wild type 
gastric proton pumps confirmed a Ki of 3.0 nM/L for vonoprazan, while the abrupt loss of affinity 
for the mutant try799ser indicated the significance of the phenyl side chain for the binding of 
vonoprazan. In addition, the authors observed that a higher total surface area and a higher 
percentage of vonoprazan was engaged into the binding site, as compared to SCH28080, showing 
that vonoprazan fills the luminal vestibular space of the proton pump more efficiently than 
SCH28080.[62] This observation might explain the slower dissociation rate of vonoprazan. Use of 
mutant models allowed to identify also some subtle conformational differences that might explain 
the higher affinity of vonoprazan for the gastric H+,K+-ATPase, as compared to SCH28080, and 
the high selectivity of vonoprazan for H+,K+-ATPase over the ubiquitous Na+,K+-ATPase.[58, 62] 
Overall, based on the above observations, a pKa of 9.3, a Ki of 3.0 nM/L and the wide binding 
surface of vonoprazan appear to be the key points that would explain its more potent and longer 
lasting antisecretory action as compared with other P-CABs. 
In vivo preclinical studies have supported the view that vonoprazan exerts a more potent and longer-
lasting antisecretory activity than previous P-CABs and PPIs. Hori et al.[59] assessed the effects of 
vonoprazan on acid secretion and pH of gastric perfusate in rats, as compared to lansoprazole and 
SCH28080. When administered to rats, vonoprazan showed maximal acid inhibitory activity at the 
dose of 4 mg/kg, while lansoprazole showed potent, but incomplete, inhibition of acid secretion at 4 
or 8 mg/kg. This finding was confirmed also under stimulation of gastric acid secretion with 2-
deoxy-D-glucose or histamine.[59] Moreover, vonoprazan increased the pH of gastric perfusate to a 
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 higher value than lansoprazole or SCH28080, and the effect of vonoprazan was more sustained than 
that of lansoprazole or SCH28080.[59] Similar results have been obtained in a subsequent study by 
the same authors, who measured the pH of gastric perfusate in rats and dogs after administration of 
vonoprazan or lansoprazole. In this study, at variance from lansoprazole, the increase in pH by 
vonoprazan was unaffected by subsequent stimulation of gastric acid secretion with histamine.[63] 
In line with these findings, Arikawa et al.[64] confirmed a more potent antisecretory activity of 
vonoprazan on histamine-induced acid secretion in rats and dogs, as compared with lansoprazole. 
 
4.1.2 Studies in humans 
Studies on healthy volunteers have shown rapid, marked, and sustained inhibition of gastric acid 
secretion with single oral doses of vonoprazan.[29, 65] In two phase I, randomized, double-blind, 
placebo-controlled, single rising-dose studies, performed in Japan and United Kingdom (UK), 
healthy male subjects received a single dose of vonoprazan (1–120 mg in Japan, and 1–40 mg in the 
UK). Acid inhibition showed a rapid onset, being dose-dependent and similar in both studies. The 
24-h intragastric pH≥4 holding time ratio (HTR) with 40 mg of vonoprazan was 92% in Japan and 
87% in the UK.[65] The same authors performed two additional phase I studies on healthy male 
subjects in Japan and UK, where vonoprazan was administered at multiple rising oral doses, ranging 
from 10 to 40 mg, once daily for 1 week, showing similar pharmacodynamics as the above 
mentioned studies.[29] In particular, the intragastric pH HTRs on day 7 displayed a good pH 
control throughout the 24-h dosing interval (pH >4 HTR >83%), including the night-time period 
(pH >4 HTR ≥73%), at the clinically recommended dose of 20 mg, with even a greater rate of acid 
inhibition observed with daily doses >20 mg. Overall, the authors concluded that 20 mg/day was 
efficient, with a fast onset of action, offering a good acid control throughout 24-h and at night-
time.[29] 
Two comparative studies of vonoprazan with PPIs in healthy volunteers carrying the CYP2C19 
extensive metabolizer genotype have been also performed.[66] Firstly, in a randomized, open-label, 
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 two-period cross-over study, vonoprazan 20 mg and esomeprazole 20 mg or rabeprazole 10 mg 
were orally administered daily for 7 days. Under these conditions, vonoprazan exerted a more rapid 
and sustained acid-inhibitory effect. Indeed, acid-inhibition was evident after the first 
administration of vonoprazan, and it was sustained over 24-h during 7 days.[66] More recently, in a 
randomized, two-period cross-over study, vonoprazan 20 mg twice daily, vonoprazan 20 mg daily, 
esomeprazole 20 mg twice daily and esomeprazole 20 mg daily were orally administered daily for 7 
days in 28 healthy volunteers [7 CYP2C19 poor metabolisers (PMs), 11 intermediate metabolisers 
(IMs) and 10 rapid metabolisers (RMs)]. Vonoprazan twice daily potently suppressed acid for 24 h, 
and was significantly superior to other regimens irrespective of CYP2C19 genotype. Vonoprazan 
daily was equivalent to esomeprazole twice daily in IMs and PMs, but superior in RMs. Thus, 
CYP2C19 genotype-dependent differences were observed in esomeprazole daily but not in 
vonoprazan twice daily or daily.[67] 
 
4.2 Pharmacokinetics 
The chemical structure of vonoprazan is characterized by a point-positive charge (pKa 9.06) that 
favors a greater accumulation in parietal cells as compared with previous P-CABs.[58] The duration 
of the antisecretory effect of vonoprazan is also dependent on its t½, which is 7.5 hours (after oral 
administration in 20 mM of KCl at pH 7).[58]  
In the two phase I studies performed in Japan and UK on healthy male subjects, plasma 
concentration–time profiles of vonoprazan at all dose levels showed a pattern of rapid absorption 
(median Tmax up to 2 h) under fasting conditions. The estimated mean elimination half-life was up 
to 9 h. The systemic exposure (i.e., maximum observed concentration, Cmax, and bioavailability, 
AUC) was slightly greater than dose proportional. The urinary excretion of unchanged vonoprazan 
over 24-h was low after all the tested doses (about 1-9%). Overall, no clear difference in 
vonoprazan pharmacokinetics was observed between Japanese and non-Japanese subjects.[65] 
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 Similar results were obtained in subsequent two phase I studies on healthy male volunteers 
performed by the same authors.[29] 
Of note, vonoprazan metabolism displays a limited influence by CYP polymorphisms.[64] In 
particular, both in healthy male volunteers and GERD patients, it has been shown that the 
pharmacokinetics and pharmacodynamics of vonoprazan were not affected by the CYP2C19 
genotype.[29, 65, 66, 68]  
 
4.3 Efficacy in GERD 
Ashida et al.[68, 69] performed two phase II, multicentre, randomised, double-blind, parallel-group 
studies in Japanese patients with endoscopically confirmed erosive esophagitis. The first study was 
designed to evaluate the efficacy of once-daily vonoprazan at 5, 10, 20 or 40 mg versus once-daily 
30 mg lansoprazole in healing erosive esophagitis at week 4, as assessed by endoscopy.[69] They 
observed that vonoprazan was effective and non-inferior to lansoprazole in healing esophagitis at all 
the tested doses. Of interest, the healing rate after two weeks of treatment with vonoprazan 20 mg 
was higher than with lansoprazole 30 mg. Moreover, although differences in the proportion of 
healed erosive esophagitis did not reach statistical significance, 20 mg or higher doses of 
vonoprazan resulted to be highly effective in patients with severe esophagitis (grades C/D). In 
conclusion, the authors recommended 20 mg/day of vonoprazan as the most suitable clinical dose 
for the management of erosive esophagitis.[69]   
In the second study, Ashida et al.[68] aimed at verifying the non-inferiority of vonoprazan 20 
mg/day versus lansoprazole 30 mg/day in patients with erosive esophagitis, and then to establish 
long-term efficacy of vonoprazan as maintenance therapy. In this study, vonoprazan and 
lansoprazole were equally effective at 8 weeks. However, there was a much higher percentage of 
patients healed at week 2 in the vonoprazan group (90.7% versus 81.9%; 95% CI: 2.105–15.448; P 
< 0.0001). Moreover, the analysis of patient subgroups showed that the proportion of patients with 
healed erosive esophagitis tended to be higher in the vonoprazan group, as compared with 
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 lansoprazole, in patients with more severe esophagitis (grades C/D) as well as in those classified as 
CYP2C19 extensive metabolisers. Subsequently, patients, who had been healed at 8 weeks, were 
randomized to receive vonoprazan 10 or 20 mg/day as maintenance therapy up to 52 weeks. Over 
this time, the recurrence rate of erosive esophagitis was low (<10%).[68] Overall, these results 
suggest a stronger and faster clinical effect with vonoprazan, which presumably results from its 
rapid and strong suppression of gastric acid secretion. 
 
4.4 Safety profile 
The safety and tolerability of vonoprazan have been investigated in the above mentioned phase I 
studies, performed by Sakurai et al.[65] on healthy male subjects volunteers. The drug was 
administered according to a single-dose escalation scheme aimed at finding up the maximum 
tolerated dose or the maximum AUC. In this setting, vonoprazan was safe and well tolerated at all 
tested doses, without relevant adverse events in the Japanese subjects and only 12 treatment-
emergent adverse events (TEAEs) in 10 subjects of the UK study. There were no serious adverse 
events in either study.[65] In two subsequent phase I studies conducted by the same authors on 
healthy male subjects, vonoprazan was administered at multiple rising oral doses, ranging from 10 
to 40 mg, once daily for 1 week, and all doses were found to be safe and well tolerated.[29] 
Likewise, in a further randomized, open-label, two-period cross-over study, vonoprazan 20 mg, 
administered daily for 7 days by oral route, was well tolerated.[66]  
In a randomized, dose-ranging study, the safety profile of vonoprazan was evaluated in patients with 
erosive esophagitis at doses of 5, 10, 20 and 40 mg once daily for 8 weeks. Overall, vonoprazan was 
safe and well tolerated at all the investigated doses.[69] Subsequently, the same authors investigated 
the long-term safety of vonoprazan in a similar study in patients with erosive esophagitis. In this 
setting, there were no new safety signals and no significant changes in laboratory values, vital signs 
or electrocardiogram findings, other than an increase in gastrin levels. Accordingly, it was 
concluded that vonoprazan at the doses of 10 and 20 mg once daily, as maintenance therapy for 52 
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 weeks, was safe and well-tolerated.[68] Of note, at variance with previous P-CABs, the vonoprazan 
structure lacks the imidazopyridine ring, which was responsible for hepatotoxicity.  
 
5. Conclusion 
Acid suppression with PPIs represents the mainstay of GERD medical treatment. However, despite 
the well-documented clinical efficacy and safety of PPIs, about 20-40% of GERD patients display 
an inadequate response to these drugs, thus underscoring the need for new drugs able to achieve a 
more potent and long-lasting inhibition of gastric acid secretion. In this context, vonoprazan, a 
novel pyrrole derivative P-CAB, has been developed as a potential alternative to PPIs for the 
management of acid-related disorders, including GERD. This drug has been shown to compete with 
K+ and to induce a selective and reversible inhibition of H+-K+-ATPase in a dose-dependent 
manner. 
Studies in preclinical models and humans have documented the ability of vonoprazan of inhibiting 
the gastric proton pump more effectively than previous P-CABs and PPIs. In particular, vonoprazan 
is endowed with a pKa of 9.3, which is higher than that of previous P-CABs and PPIs. Therefore, 
its pharmacodynamic activity is not affected by higher values of pH and the compound is resistant 
to strong acidity. Once in an acidic environment, vonoprazan is instantly protonated. It is then 
highly concentrated and remains in its protonated form within the secretory canalicula of gastric 
parietal cells, where it binds and inhibits the proton pumps. Of note, at variance from PPIs, the acid 
inhibitory effect of vonoprazan does not require proton pump activation and it is unaffected by the 
gastric secretory activity, thus resulting in a more rapid acid inhibition and elevation of gastric pH 
than PPIs. Consistently with these patterns, vonoprazan has been shown to exert a more potent and 
longer-lasting inhibitory effect on gastric acid secretion, as compared with PPIs and previous P-
CABs. The specific advantages of vonoprazan, as compared to previous P-CABs, include a slower 
dissociation rate from the H+,K+-ATPase, that accounts for a longer duration of action, and the lack 
of hepatotoxicity that has precluded the clinical use of other PCABs. Molecular modellings of 
D
ow
nl
oa
de
d 
by
 [R
M
IT
 U
niv
ers
ity
 L
ibr
ary
] a
t 2
1:2
3 1
9 J
uly
 20
16
 
 vonoprazan binding to H+,K+-ATPase have suggested that its specific conformational features 
represent a possible explanation whereby its exit from the binding site is more hindered than 
previous P-CABs. As a result of these properties, human studies have shown that vonoprazan can 
exert its full antisecretory activity since the first dose and provide sustained control of acid 
secretion, including the nocturnal period. Furthermore, at variance with most of current PPIs, the 
metabolic disposition of vonoprazan is not significantly influenced by CYP2C19 genetic 
polymorphism, thus resulting in a low interindividual variability. Whether these favorable 
pharmacological properties will translate into greater clinical benefits in GERD patients, as 
compared with current PPI therapy, has yet to be conclusively established. 
 
6. Expert opinion  
PPIs have a number of shortcomings, which arise from their pharmacological properties. Firstly, 
PPIs display a large interindividual variability in their own disposition, which depends on both 
genetic and non-genetic factors, and therefore the degree of acid achieved by a standard, once-daily 
dose of any available PPI, is highly variable over the 24-h, with possible persistence of nocturnal 
acidity. In addition, all available PPIs need several days to achieve optimal efficacy. Furthermore, a 
major drawback of PPIs is the requirement for acid secretion within the secretory canalicula of 
parietal cells to promote the accumulation of the prodrug and the conversion into its active form.  
Consistently with the lack of an ideal drug, there are still some unmet clinical needs in GERD that 
deserve consideration and await for adequate solutions. These include: the management of patients 
with reflux symptoms who do not respond adequately to PPI therapy; a faster onset of symptom 
relief; the optimization of acid inhibition with regard for the daily time course of gastric pH control, 
particularly over the night. In this context, an innovative approach has been the development of a 
new class of H+,K+-ATPase inhibitors, designated as PCABs, among which vonoprazan has been 
currently approved in Japan for the treatment of acid-related diseases, including GERD, erosive 
esophagitis, gastric and duodenal ulcer, and Helicobacter pylori eradication. 
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 Vonoprazan inhibits H+,K+-ATPase in a reversible and K+-competitive manner, providing a fast 
onset of action. At variance from all the available PPIs, vonoprazan acts directly on H+,K+-
ATPase, without requiring acid activation. Since the onset of acid inhibition occurs irrespectively of 
the activity of proton pumps, vonoprazan does not require specific timing with respect to food 
intake. In addition, as vonoprazan is stable in acidic environments, no gastro-protective coating is 
required. In line with these pharmacological properties, experimental studies and clinical 
pharmacological investigations in healthy volunteers have confirmed a more rapid, potent and 
prolonged inhibition of acid secretion by vonoprazan, including a better nighttime acid control, as 
compared with PPIs. At last, vonoprazan is not metabolized by CYP2C19, allowing for less 
antisecretory variability and a lower risk of drug interactions among patients, particularly those 
receiving poly-drug therapies. 
The results of trials in Japanese patients with erosive esophagitis have shown that the healing rate 
after two weeks of treatment with vonoprazan was higher than lansoprazole, with the proportion of 
patients with healed erosive esophagitis displaying a higher trend in the vonoprazan group, in 
patients with more severe esophagitis.  
Since vonoprazan provides a more effective control of intragastric pH, it is expected that it will 
have a significant favorable impact on GERD management. In particular, patients complaining of 
persistent symptoms late in the day or at night will be among the expected beneficiaries of the 
improved pharmacological properties of vonoprazan. The fast onset of action, with a full acid 
inhibition since the first dose, is expected also to be clinically relevant, making vonoprazan suitable 
for on-demand maintenance therapy.  
Besides a number of expected benefits, the clinical use of vonoprazan raises also some issues that 
deserve verification and careful investigations. First, given the limited clinical data available on 
vonoprazan, additional and more extensive randomized controlled clinical trials are urgently 
required to confirm its actual advantages in GERD patients, with and without erosive esophagitis. In 
particular, comparative clinical studies of vonoprazan versus second generation PPis (rabeprazole 
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 and esomeprazole), assessing the potency and time course of gastric pH control, as well as the 
suitability of vonoprazan for both short- and long-term maintenance of GERD, including healing of 
erosive esophagitis and symptom relief, are warranted. Second, special attention should be paid to 
randomized controlled trials evaluating the potential effectiveness of vonoprazan in patients with 
refractoriness to therapy with current PPIs. Indeed, considering that not all GERD patients will 
require vonoprazan as first line therapy, we deem of interest to implement studies on targeted 
patient populations, who could take particular advance from a more-potent acid inhibition (i.e., 
patients with atypical GERD symptoms). Third, other areas deserving attention include the potential 
interactions of vonoprazan with other drugs, as well as the overall safety profile of vonoprazan 
given over long-term treatment periods. 
 Drug Summary Box 
 
Drug name Vonoprazan fumarate 
Phase III 
Indication Acid-related disease (including gastro-
esophageal reflux disease and peptic 
ulcer) 
Adjunct to Helicobacter pylori 
eradication 
Pharmacology description Potassium-competitive acid blocker 
(P-CAB) 
Route of administration Oral 
Chemical structure 
Pivotal trial(s) [29, 67, 68, 69] 
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